{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:55:44Z","timestamp":1790117744354,"version":"4.0.1"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T00:00:00Z","timestamp":1654819200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017950","name":"Shanghai Municipal Health Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017950","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["RJTJ\u2013JX\u2013001"],"award-info":[{"award-number":["RJTJ\u2013JX\u2013001"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020737","name":"Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020737","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.eclinm.2022.101535","type":"journal-article","created":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T05:33:10Z","timestamp":1656653590000},"page":"101535","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"special_numbering":"C","title":["Toxicity spectrum of immunotherapy in advanced lung cancer: A safety analysis from clinical trials and a pharmacovigilance system"],"prefix":"10.1016","volume":"50","author":[{"given":"Yi-Dan","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Jie","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang-Li","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Er-Li","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing-Long","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1245-9690","authenticated-orcid":false,"given":"Zhi-Chun","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hou-Wen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.eclinm.2022.101535_bib0001","first-page":"1","article-title":"Immunotherapy in non-small cell lung cancer: update and new insights","volume":"7","author":"Mielgo-Rubio","year":"2021","journal-title":"J Clin Transl Res"},{"issue":"1","key":"10.1016\/j.eclinm.2022.101535_bib0002","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s13046-021-01987-7","article-title":"Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer","volume":"40","author":"Zhang","year":"2021","journal-title":"J Exp Clin Cancer Res: CR"},{"issue":"8","key":"10.1016\/j.eclinm.2022.101535_bib0003","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s11886-021-01530-2","article-title":"Mechanisms driving immune-related adverse events in cancer patients treated with immune checkpoint inhibitors","volume":"23","author":"Lee","year":"2021","journal-title":"Curr Cardiol Rep"},{"issue":"2","key":"10.1016\/j.eclinm.2022.101535_bib0004","doi-asserted-by":"crossref","first-page":"e001235","DOI":"10.1136\/jitc-2020-001235","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma","volume":"8","author":"Neelapu","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.eclinm.2022.101535_bib0005","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.eclinm.2022.101535_bib0006","doi-asserted-by":"crossref","first-page":"9139","DOI":"10.2147\/CMAR.S218756","article-title":"Management of immune checkpoint inhibitor toxicities","volume":"12","author":"Durrechou","year":"2020","journal-title":"Cancer Manage Res"},{"issue":"23","key":"10.1016\/j.eclinm.2022.101535_bib0007","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","article-title":"Real-world evidence - what is it and what can it tell us?","volume":"375","author":"Sherman","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2022.101535_bib0008","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3389\/fonc.2017.00056","article-title":"Incidence of immune-related adverse events with program death receptor-1- and program death receptor-1 ligand-directed therapies in genitourinary cancers","volume":"7","author":"Maughan","year":"2017","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.eclinm.2022.101535_bib0009","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ygyno.2021.05.012","article-title":"Risk of pneumonitis in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials and a pharmacovigilance study of the FAERS database","volume":"162","author":"Ma","year":"2021","journal-title":"Gynecol Oncol"},{"issue":"10","key":"10.1016\/j.eclinm.2022.101535_bib0010","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1093\/jnci\/djab035","article-title":"Association between sex and immune-related adverse events during immune checkpoint inhibitor therapy","volume":"113","author":"Jing","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eclinm.2022.101535_bib0011","first-page":"n160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ (Clinical research ed)"},{"issue":"1","key":"10.1016\/j.eclinm.2022.101535_bib0012","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.eclinm.2022.101535_bib0013","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ (Clinical research ed)"},{"issue":"10","key":"10.1016\/j.eclinm.2022.101535_bib0014","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-047046","article-title":"Efficacy of left ventricular unloading strategies during venoarterial extracorporeal membrane oxygenation in patients with cardiogenic shock: a protocol for a systematic review and Bayesian network meta-analysis","volume":"11","author":"Zhang","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.eclinm.2022.101535_bib0015","doi-asserted-by":"crossref","first-page":"k4226","DOI":"10.1136\/bmj.k4226","article-title":"Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis","volume":"363","author":"Xu","year":"2018","journal-title":"BMJ (Clinical research ed)"},{"issue":"8","key":"10.1016\/j.eclinm.2022.101535_bib0016","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"10.1016\/j.eclinm.2022.101535_bib0017","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1186\/s40425-019-0754-2","article-title":"Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system","volume":"7","author":"Zhai","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.eclinm.2022.101535_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103351","article-title":"Meta-analysis of immune-related adverse events in phase 3 clinical trials assessing immune checkpoint inhibitors for lung cancer","volume":"162","author":"Berti","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.eclinm.2022.101535_bib0019","article-title":"Immune-related adverse events associated with immune checkpoint inhibitors for advanced non-small cell lung cancer: a network meta-analysis of randomized clinical trials","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.eclinm.2022.101535_bib0020","doi-asserted-by":"crossref","DOI":"10.1007\/s00262-022-03140-5","article-title":"Severe immune-related adverse events of immune checkpoint inhibitors for advanced non-small cell lung cancer: a network meta-analysis of randomized clinical trials","author":"Gu","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.eclinm.2022.101535_bib0021","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.760737","article-title":"A network comparison on safety profiling of immune checkpoint inhibitors in advanced lung cancer","volume":"12","author":"Yan","year":"2021","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.eclinm.2022.101535_bib0022","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00408-021-00425-x","article-title":"Lessons from pharmacovigilance: pulmonary immune-related adverse events after immune checkpoint inhibitor therapy","volume":"199","author":"Reese","year":"2021","journal-title":"Lung"},{"issue":"3","key":"10.1016\/j.eclinm.2022.101535_bib0023","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1007\/s12020-020-02355-9","article-title":"Mapping endocrine toxicity spectrum of immune checkpoint inhibitors: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase","volume":"69","author":"Bai","year":"2020","journal-title":"Endocrine"},{"issue":"18","key":"10.1016\/j.eclinm.2022.101535_bib0024","doi-asserted-by":"crossref","first-page":"6576","DOI":"10.1002\/cam4.3198","article-title":"Renal adverse effects following the use of different immune checkpoint inhibitor regimens: a real-world pharmacoepidemiology study of post-marketing surveillance data","volume":"9","author":"Chen","year":"2020","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.eclinm.2022.101535_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11060-019-03273-1","article-title":"Neurological and related adverse events in immune checkpoint inhibitors: a pharmacovigilance study from the Japanese Adverse Drug Event Report database","volume":"145","author":"Sato","year":"2019","journal-title":"J Neurooncol"},{"key":"10.1016\/j.eclinm.2022.101535_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.105866","article-title":"Myocarditis following the use of different immune checkpoint inhibitor regimens: a real-world analysis of post-marketing surveillance data","volume":"76","author":"Fan","year":"2019","journal-title":"Int Immunopharmacol"},{"issue":"8","key":"10.1016\/j.eclinm.2022.101535_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102586","article-title":"Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities","volume":"19","author":"Allenbach","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.eclinm.2022.101535_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107498","article-title":"Immune-related adverse events associated with immune checkpoint inhibitors: an updated comprehensive disproportionality analysis of the FDA adverse event reporting system","volume":"95","author":"Chen","year":"2021","journal-title":"Int Immunopharmacol"},{"issue":"suppl 7","key":"10.1016\/j.eclinm.2022.101535_bib0029","doi-asserted-by":"crossref","first-page":"vii59","DOI":"10.1093\/rheumatology\/kez308","article-title":"Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors","volume":"58","author":"Weinmann","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.eclinm.2022.101535_bib0030","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.cell.2018.09.035","article-title":"A paradigm shift in cancer immunotherapy: from enhancement to normalization","volume":"175","author":"Sanmamed","year":"2018","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.eclinm.2022.101535_bib0031","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/S1470-2045(20)30494-0","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial","volume":"21","author":"Ascierto","year":"2020","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.eclinm.2022.101535_bib0032","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","volume":"20","author":"Robert","year":"2019","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.eclinm.2022.101535_bib0033","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1378\/chest.121.4.1278","article-title":"Association of malignancy with diseases causing interstitial pulmonary changes","volume":"121","author":"Bouros","year":"2002","journal-title":"Chest"},{"issue":"7","key":"10.1016\/j.eclinm.2022.101535_bib0034","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S1470-2045(17)30380-7","article-title":"Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial","volume":"18","author":"Shaverdian","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eclinm.2022.101535_bib0035","article-title":"Cardiotoxicity induced by immune checkpoint inhibitors: a pharmacovigilance study from 2014 to 2019 based on FAERS","volume":"12","author":"Chen","year":"2021","journal-title":"Front Pharmacol"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537022002656?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537022002656?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T19:14:32Z","timestamp":1762888472000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537022002656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":35,"alternative-id":["S2589537022002656"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2022.101535","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toxicity spectrum of immunotherapy in advanced lung cancer: A safety analysis from clinical trials and a pharmacovigilance system","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2022.101535","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101535"}}